Albert B. Sabin M.D.
The Children's Hospital
Research Foundation
Eland Avenue and Bethesda
CINCINNATI 29, Ohio, U.S.A.

Dear Doctor Sabin,

in connection with the development in the field of poliomyelitis vaccine, live, oral, especially since the last Symposium of the European Association against Poliomyelitis in Oxford, in which unfortunately quite diverging opinions were represented, I would appreciate very much to know your point of view regarding the following problem:

In spite our determination to follow as close as possible your recommendations and to work exclusively with your strains it could become necessary - in complying with the recommendations of certain health authorities - to replace an attenuated representative of a serological type of poliomyelitis virus by another attenuated strain. What should be done in case of requirements which prescribe for a campaign bi- or tri-valent poliomyelitis vaccine, live, oral, which includes one or two attenuated virus strains manufactured from your seed virus and from attenuated strains of an other origin? Should such a combination be denominated Sabin vaccine or something like "partial" Sabin?

With the kindest regards

Sincerely yours

Enclosure: Agreed statement of the VII Symposium Oxford